Full-Time
Mendix Developer
Posted on 3/17/2025
Agilent Technologies
10,001+ employees
Provides eProcurement automation and hosted catalogs
No salary listed
Bawal, India
In Person
 Software Engineering (2) |
|---|
| , |
- Minimum of 4+ years of work experience in product-based workflow tool development with demonstrable previous experience as a lead developer role
- Proven ability and curiosity to quickly learn new technologies and a keen interest in working with the global team for solving complex business needs
- Strong background in innovation development projects and comfortable with managing the funnel from relatively vague requirements to a well-defined project with committed stakeholders
- Excellent written and oral communication skills in English
- Minimum 8 years of knowledge of the following: SSIS, SSRS, SQL Procedures, .Net, Classic ASP/ASP.NET / C# / VB.NET, ASP / HTML, E-Mail HTML, JavaScript, CSS / DHTML, MS SQL, Window Application
- Understanding of the boundary applications Like SAP, Active directory, Servers, server migrations etc.
- Good understanding and the working Knowledge on QA and production environment
- Proven experience in working in Sprints and agile methodology, project management
- Experience in OOPS, Java/J2EE, Model-Driven Development. Knowledge of modern UI Technologies
- Hands-on development experience in Mendix or working on Low code platforms
- Bachelor's in computer science or equivalent technical degree
- Act as a liaison among stakeholders to analyze, prioritize, communicate and validate requirements for changes to business processes and workflows
- Create comprehensive, accurate business and functional requirements and present them clearly to the stakeholders and delivery team
- Work with Developers, Architects, Managers, Business Stakeholders to plan timelines and ensure timely delivery of a high-quality overall solution that meets business requirements
- Develop an understanding of applications; understand the data model and its mapping to the various business processes
- Proven track of implementing the workflow projects E2E and a complete understanding of SDLC, defining the project scope, goals, deliverables and timelines
- Gathering requirements using workshops or focus groups, use prototyping and early demo, reiterative user testing of designs/workflows for faster and accurate implementations of the change requests
- Demonstrate the ability to project manage using Agile/Waterfall methodologies, effort estimation, and detailed planning by effectively defining and estimating work breakdowns
- Review and ensure the world-class quality of the deliverables, demonstrating proactive behaviour and uncompromising integrity on the accuracy and the committed timelines of each task assigned
- Familiarity with the projects on Sales and marketing & order management (Q2C) is an added advantage
- Preferably, deep understanding of the API development and knowledge of creating APIs
- Preferably, experience on RPA solutions using Blue Prism
Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.
Company Size
10,001+
Company Stage
IPO
Headquarters
Santa Clara, California
Founded
1999
Simplify's Take
What believers are saying
- Biocare Medical adds over 300 pathology antibodies and $90 million 2025 revenue.
- Cytation 9 and xCELLigence software deepen automation-friendly research workflows.
- Veeda and C-CAMP expand Agilent’s access to India’s growing biologics ecosystem.
What critics are saying
- Keytruda-linked diagnostics face direct exposure to Merck label and reimbursement changes.
- Biocare integration costs can erase expected growth if cross-sell stalls.
- Tariffs and supply-chain inflation squeeze margins in Agilent’s instrument-heavy business model.
What makes Agilent Technologies unique
- Agilent spans instruments, software, consumables, and services across 110 countries.
- Its FDA-approved PD-L1 IHC 22C3 pharmDx extends a recurring diagnostics franchise.
- Bulk Alarm Resolution Technology brings Raman screening into airport security workflows.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Agilent Technologies who can refer or advise you
Benefits
Remote Work Options
Performance Bonus
Stock Options
Company News
Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.
Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.
Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.
Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t
Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction